Millennium Pharmacon International Telah Serap 50 percent Capex - KONTAN
| SDPC Stock | IDR 129.00 1.00 0.77% |
About 62% of Millennium Pharmacon's investor base is looking to short. The analysis of current outlook of investing in Millennium Pharmacon International suggests that many traders are alarmed regarding Millennium Pharmacon's prospects. Millennium Pharmacon's investing sentiment shows overall attitude of investors towards Millennium Pharmacon International.
Millennium |
Millennium Pharmacon International Telah Serap 50 percent Capex KONTAN
Read at news.google.com
 |
Millennium Pharmacon Fundamental Analysis
We analyze Millennium Pharmacon's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Millennium Pharmacon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Millennium Pharmacon based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Millennium Pharmacon is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Millennium Pharmacon Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Millennium Pharmacon stock to make a market-neutral strategy. Peer analysis of Millennium Pharmacon could also be used in its relative valuation, which is a method of valuing Millennium Pharmacon by comparing valuation metrics with similar companies.
Peers
Millennium Pharmacon Related Equities
| TMPO | Tempo Inti | 1.69 | ||||
| WICO | Wicaksana Overseas | 0.00 | ||||
| TGKA | Tigaraksa Satria | 0.78 | ||||
| SHID | Hotel Sahid | 3.33 | ||||
| WAPO | Wahana Pronatural | 3.51 |
Other Information on Investing in Millennium Stock
Millennium Pharmacon financial ratios help investors to determine whether Millennium Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Millennium with respect to the benefits of owning Millennium Pharmacon security.